Project Grant K99AI199040
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $152,600 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Southwestern Medical Center on October 7, 2026. The award supports a basic science research project examining the molecular and cellular mechanisms of B-alanyl tryptamine (BATT), a recently discovered pheromone synthesized by male schistosomes that triggers...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $415,000 to The University of Texas Southwestern Medical Center under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 7, 2026, with a completion date of April 30, 2031. This research grant supports investigator-initiated biomedical research aimed at establishing and expanding scientific knowledge regarding infectious diseases, allergic conditions, and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Texas at Arlington a Project Grant of $533,850 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. This research initiative focuses on elucidating the pathogenesis of Staphylococcus aureus thymidine-dependent small-colony variants (TD-SCVs) in cystic fibrosis patients. The project will investigate how...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center a $1.14 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 11, 2025, for a five-year research initiative extending through August 31, 2030. This award funds investigator-initiated research investigating the mechanisms of Mycobacterium tuberculosis (MTB) transmission through...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center a Project Grant totaling $828,340 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 6, 2026, through January 31, 2031. This research project will deliver investigative outputs focused on understanding HIV-1 transcription reactivation mechanisms in reservoir cells, specifically examining the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Texas Health Science Center at Houston $418,360 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025, for a project concluding July 31, 2027. This Project Grant funds systematic analysis of Treponema pallidum gene expression under host infection-related conditions to advance understanding of syphilis pathogenesis and inform vaccine...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center a $3.28 million Project Grant on August 21, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The four-year research initiative, scheduled for completion on July 31, 2029, focuses on elucidating the mechanisms by which host ubiquitin ligases and deubiquitinases regulate immune responses against Mycobacterium tuberculosis...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $249,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. The award supports research to identify conserved antiviral immune factors that restrict arbovirus replication in both insect and mammalian hosts. The primary deliverable is the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $927,025 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Texas Biomedical Research Institute on May 11, 2026, with completion targeted for April 30, 2031. The award funds research investigating IL-21-IGFC (Interleukin-21 Immunoglobulin Fc fusion) therapy as an adjunctive treatment to improve immune reconstitution in individuals with tuberculosis (TB)...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center a Project Grant totaling $596,318 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 10, 2026 through January 31, 2031. The award supports research investigating virulence factor functions in non-typhoidal Salmonella typhimurium, specifically examining how bacterial effector proteins coordinate...
Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center a Project Grant totaling $140,910 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period May 29, 2026 through April 30, 2028. This biomedical research award supports investigator-initiated research investigating the molecular mechanisms by which testosterone influences Staphylococcus aureus pathogenesis during bloodstream infections (BSIs). The research project applies a multidisciplinary approach integrating molecular biology, biochemistry, and liquid chromatography-mass spectrometry (LC-MS) analytical methodologies to elucidate sex-specific differences in infection outcomes and disease severity, with the ultimate objective of informing the development of sex-specific treatment strategies for male patients experiencing worse outcomes from S. aureus BSIs. The research deliverables under this award include scientific findings addressing the critical knowledge gap regarding the role of testosterone in shaping bacterial behavior within the bloodstream environment. Expected products include peer-reviewed publications, data characterizing how testosterone regulates bacterial pathogenic mechanisms, and mechanistic insights that could open new avenues for therapeutic intervention targeting the quorum-sensing systems regulated by testosterone exposure. These research outcomes are intended to improve clinical outcomes for male patients with S. aureus BSIs, which represent a significant global health threat accounting for over 1.2 million deaths annually worldwide, and contribute to the broader scientific knowledge base on infectious disease pathogenesis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $140.9k | 6/1/26 |